LEO Pharma A/S
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From LEO Pharma A/S
Falling At The Start Line: Chinese Firms Face Multiple Commercial Challenges Beyond Price, Coverage
Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. In this case study, Scrip takes a deep dive into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations.
Big Pharma Companies Have Higher US FDA Approval Percentage Than Everybody Else
Almost 80% of novel agent submissions from the biggest companies were approved in recent years, compared with a 60% approval rate for the rest of the industry, according to a Pink Sheet analysis of FDA approval decisions since 2021.
How Two Medtech CEOs Are (And Aren’t) Using ChatGPT In Their Businesses
Two medtech executives talked to Medtech Insight about how they started integrating ChatGPT into their start-ups to help with writing marketing copy, develop websites and presentations, identify KOLs and conferences, and other content.
Lilly Strikes Out With The FDA For Second Time This Year With Mirikizumab CRL
With mirikizumab delayed until Lilly overcomes the FDA’s manufacturing concerns, the company has fallen behind on its goal of five approvals in 2023.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- LEO Pharma Inc.
- Peplin, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.